The company said organic sales for Q3 of fiscal 2026 (Q3 FY 2026) grew 3% from a year earlier. It said volume rose +2% and pricing rose +1%, and that organic sales grew in 10 product categories and 7 regions.

8-KRegulation FD DisclosureFiled Apr 24, 2026Period of report Apr 24, 2026Summary published (UTC) Oct 2, 2026

Key points

AI summary

The company said organic sales for Q3 of fiscal 2026 (Q3 FY 2026) grew 3% from a year earlier. It said volume rose +2% and pricing rose +1%, and that organic sales grew in 10 product categories and 7 regions.
Procter & Gamble said Core EPS for Q3 was $1.59, up 3% from $1.54 a year earlier, and currency-neutral Core EPS was $1.54. It said Core gross margin was 50.0% (51.0% a year earlier) and Core operating margin was 22.2% (23.0% a year earlier).
The company said the Glad joint venture agreement with Clorox expired in January 2026 and that Clorox bought the company's minority interest at fair market value for $476 million. It said it accounted for the transaction as a dissolution of the joint venture business and recorded an after-tax gain of $261 million.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

Fiscal 2026 Q3 Organic Sales Growth of 3%

The company said organic sales for Q3 of fiscal 2026 (Q3 FY 2026) grew 3% from a year earlier. It said volume rose +2% and pricing rose +1%, and that organic sales grew in 10 product categories and 7 regions.

Source · Based on the filing body and exhibits

Q3 Core EPS of $1.59, Core Margin Changes

Procter & Gamble said Core EPS for Q3 was $1.59, up 3% from $1.54 a year earlier, and currency-neutral Core EPS was $1.54. It said Core gross margin was 50.0% (51.0% a year earlier) and Core operating margin was 22.2% (23.0% a year earlier).

Source · Based on the filing body and exhibits

Sale of $476 million Glad Joint Venture Stake

The company said the Glad joint venture agreement with Clorox expired in January 2026 and that Clorox bought the company's minority interest at fair market value for $476 million. It said it accounted for the transaction as a dissolution of the joint venture business and recorded an after-tax gain of $261 million.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.